PDCD1 and cancer: The main targets of current cancer immunotherapy are coinhibitory molecules known as immune checkpoint molecules, which negatively modulate the activation of T cell responses, such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4.